$3.23
0.92% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

MacroGenics, Inc. Stock price

$3.23
-0.41 11.26% 1M
-0.89 21.60% 6M
-6.39 66.42% YTD
-6.73 67.57% 1Y
-13.53 80.73% 3Y
-7.53 69.98% 5Y
-32.44 90.94% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 0.92%
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

Key metrics

Market capitalization $202.73m
Enterprise Value $36.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.26
P/S ratio (TTM) P/S ratio 1.43
P/B ratio (TTM) P/B ratio 1.69
Revenue growth (TTM) Revenue growth 16.68%
Revenue (TTM) Revenue $141.33m
EBIT (operating result TTM) EBIT $-107.09m
Free Cash Flow (TTM) Free Cash Flow $-61.71m
Cash position $200.36m
EPS (TTM) EPS $-1.57
P/E forward negative
P/S forward 1.27
EV/Sales forward 0.23
Short interest 10.19%
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a MacroGenics, Inc. forecast:

4x Buy
36%
7x Hold
64%

Analyst Opinions

11 Analysts have issued a MacroGenics, Inc. forecast:

Buy
36%
Hold
64%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
141 141
17% 17%
100%
- Direct Costs 14 14
31% 31%
10%
127 127
27% 27%
90%
- Selling and Administrative Expenses 48 48
14% 14%
34%
- Research and Development Expense 178 178
16% 16%
126%
-100 -100
4% 4%
-71%
- Depreciation and Amortization 7.39 7.39
33% 33%
5%
EBIT (Operating Income) EBIT -107 -107
0% 0%
-76%
Net Profit -98 -98
296% 296%
-69%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concern...
Neutral
GlobeNewsWire
26 days ago
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
Neutral
GlobeNewsWire
about 2 months ago
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 339
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today